Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies, suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurion, Ronit, Rozovski, Uri, Itchaki, Gilad, Gafter-Gvili, Anat, Leibovitch, Chiya, Raanani, Pia, Ben-Zvi, Haim, Szwarcwort, Moran, Taylor-Abigadol, Mor, Dann, Eldad J., Horesh, Nurit, Inbar, Tsofia, Tzoran, Inna, Lavi, Noa, Fineman, Riva, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883526/
https://www.ncbi.nlm.nih.gov/pubmed/34320790
http://dx.doi.org/10.3324/haematol.2021.279216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883526/
https://www.ncbi.nlm.nih.gov/pubmed/34320790
http://dx.doi.org/10.3324/haematol.2021.279216

Ejemplares similares